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Guidelines and recommendations should help the health
professionals to make decisions in their daily practice.
However, the ﬁnal decisions concerning an individual
patient must be made by the responsible health profession-
al(s) in consultation with the patient and caregiver as
appropriate.
2 Introduction
Aortic diseases contribute to the wide spectrum of arterial
diseases: aortic aneurysms (AA), acute aortic syndromes (AAS)
including aortic dissection (AD), intramural haematoma (IMH),
penetrating atherosclerotic ulcer (PAU) and traumatic aortic
injury (TAI), pseudoaneurysm, aortic rupture, atherosclerotic
and inﬂammatory affections, genetic diseases (e.g. Marfan
syndrome) and congenital abnormalities including the coarc-
tation of the aorta (CoA).Fig. 1 – Segments of the ascending and desce3 The normal and the ageing aorta
The aorta is the ultimate conduit, carrying, in an average
lifetime, almost 200 million litres of blood to the body. It is
divided by the diaphragm into the thoracic and abdominal
aorta (Fig. 1). In healthy adults, aortic diameters do not usually
exceed 40 mm and taper gradually downstream. In this regard,
the rate of aortic expansion is about 0.9 mm in men and
0.7 mm in women for each decade of life.
4 Assessment of the aorta
4.1 Clinical examination
While aortic diseases may be clinically silent in many cases, a
broad range of symptoms may be related to different aortic
diseases. In some situations, physical examination can be
directed by the symptoms and includes palpation and
auscultation of the abdomen and ﬂank in the search fornding aorta. rPA, right pulmonary artery.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 2 9 7 – e 3 1 9 e301prominent arterial pulsations or turbulent blood ﬂow causing
murmurs.
4.2 Laboratory testing
Baseline laboratory assessment includes cardiovascular
risk factors. Laboratory testing plays a minor role in the
diagnosis of acute aortic diseases but is useful for differential
diagnoses.
4.3 Imaging
The aorta is a complex geometric structure and several
measurements are useful to characterize its shape and
size. Diameter measurements should be made perpendicular
to the axis of ﬂow of the aorta (Fig. 2). Standardized measure-
ments will help to better assess changes in aortic size over
time.Fig. 2 – Thoracic and abdominal aorta in a three-dimensional re
reconstruction (MPR) along the centreline (left middle part), straig
I) (right side), orthogonal to the centreline orientated cross-sectio
report aortic diameters: (A) sinuses of Valsalva; (B) sinotubular ju
aortic arch (aorta at the origin of the brachiocephalic trunk); (E) m
arteries); (F) proximal descending thoracic aorta (approximately 
aorta (level of the pulmonary arteries as easily identifiable land
origin; (J) right before aortic bifurcation.
Provided by F Nensa, Institute of Diagnostic and Interventional 4.3.1 Chest X-ray
Chest X-ray obtained for other indications may detect
abnormalities of aortic contour or size. Chest X-ray is,
however, only of limited value for diagnosing an AAS.
4.3.2 Ultrasound
4.3.2.1 Transthoracic echocardiography (TTE). Echocardio-
graphic evaluation of the aorta is a routine part of the standard
echocardiographic examination. Transthoracic echocardiogra-
phy is an excellent imaging modality for serial measurement of
maximal aortic root diameters for evaluation of aortic regurgi-
tation, and timing for elective surgery in cases of TAA. TTE often
sufﬁces for screening. Aortic arch aneurysm, plaque calciﬁca-
tion, thrombus, or a dissection membrane may be detectable if
image quality is adequate. Aortic coarctation can be suspected
by continuous-wave Doppler; a patent ductus arteriosus may also
be identiﬁable by colour Doppler. The lower abdominal aorta,
below the renal arteries, can be visualized to rule out AAA.construction (left lateral image), parasagitale multiplanar
htened-MPR along the centreline with given landmarks (A–
ns at the landmarks (A–J). Landmarks A–J should be used to
nction; (C) mid ascending aorta (as indicated); (D) proximal
id aortic arch (between left common carotid and subclavian
2 cm distal to left subclavian artery); (G) mid descending
marks, as indicated); (H) at diaphragm; (I) at the celiac axis
Radiology, Essen.
Recommendations on imaging of the aorta.
Recommendations Classa Levelb
It is recommended that diameters be
measured at pre-speciﬁed anatomical
landmarks, perpendicular to the
longitudinal axis.
I C
In the case of repetitive imaging of the aorta
over time, to assess change in diameter, it
is recommended that the imaging
modality with the lowest iatrogenic risk be
used.
I C
In the case of repetitive imaging of the aorta
over time to assess change in diameter, it
is recommended that the same imaging
modality be used, with a similar method
of measurement.
I C
It is recommended that all relevant aortic
diameters and abnormalities be reported
according to the aortic segmentation.
I C
It is recommended that renal function,
pregnancy, and history of allergy to
contrast media be assessed, in order to
select the optimal imaging modality of the
aorta with minimal radiation exposure,
except for emergency cases.
I C
The risk of radiation exposure should be
assessed, especially in younger adults and
in those undergoing repetitive imaging.
IIa B
Aortic diameters may be indexed to the
body surface area, especially for the
outliers in body size.
IIb B
a Class of recommendation.
b Level of evidence.
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tive proximity of the oesophagus and the thoracic aorta
permits high-resolution images with higher-frequency. Also,
multi-plane imaging permits improved assessment of the
aorta from its root to the descending aorta. Real-time 3D TOE
appears to offer some advantages over 2D TOE.
4.3.2.3 Abdominal ultrasound. Duplex ultrasound provides
additional information on aortic ﬂow. Colour Doppler is of
great interest in the case of abdominal aorta dissection, to
detect perfusion of both false and true lumen and potential re-
entry sites or obstruction of tributaries (e.g. the iliac arteries).
Contrast-enhanced ultrasound is useful in detecting, localiz-
ing, and quantifying endoleaks when this technique is used to
follow patients after EVAR.
4.3.3 Computed tomography (CT)
Computed tomography plays a central role in the diagnosis,
risk stratiﬁcation, and management of aortic diseases (Fig. 2).
CT allows detection of the location of the diseased segment,
the maximal diameter of dilation, the presence of atheroma,
thrombus, IMH, penetrating ulcers, calciﬁcations and, in
selected cases, the extension of the disease to the aortic
branches. In most patients with suspected AD, CT is the
preferred initial imaging modality. Similar diagnostic accuracy
has been reported for detecting traumatic aortic injury. Other
features of AAS, such as penetrating ulcers, thrombus, pseudo-
aneurysm, and rupture, are readily depicted by CT.
4.3.4 Positron emission tomography/computed tomography
(PET/CT)
PET/CT imaging is based on the distribution of the F-
ﬂuorodeoxyglucose (FDG), which is taken up with high afﬁnity
by hypermetabolic cells, and can be used to detect vascular
inﬂammation in large vessels. The advantages of PET may be
combined with CT imaging with good resolution.
4.3.5 Magnetic resonance imaging
The salient features necessary for clinical decision-making,
such as maximal aortic diameter, shape and extent of the
aorta, involvement of aortic branches in aneurysmal dilation
or dissection, relationship to adjacent structures, and pres-
ence of mural thrombus, are reliably depicted by MRI.Table 1 – Comparison of methods for imaging the aorta.
Advantages/disadvantages TTE TOE 
Ease of use +++ ++ 
Diagnostic reliability + +++ 
Bedside/interventional usea ++ ++ 
Serial examinations ++ + 
Aortic wall visualizationc + +++ 
Cost   
Radiation 0 0 
Nephrotoxicity 0 0 
+ means a positive remark and  means a negative remark. The numbe
a IVUS can be used to guide interventions (see web addenda).
b +++ only for follow-up after aortic stenting (metallic struts), otherwise
c PET can be used to visualize suspected aortic inﬂammatory disease.
CT = computed tomography; MRI = magnetic resonance imaging; TOE = tran4.3.6 Aortography
Catheter-based invasive aortography visualizes the aortic
lumen, side branches, and collaterals. As a luminography
technique, angiography provides exact information about the
shape and size of the aorta, as well as any anomalies, although
diseases of the aortic wall itself are missed, as well as
thrombus-ﬁlled discrete aortic aneurysms (Table 1).
4.3.7 Intravascular ultrasound (IVUS)
To optimize visualization of the aortic wall, IVUS can be used,
particularly during endovascular treatment.CT MRI Aortography
+++ ++ +
+++ +++ ++
  ++
++(+)b +++ 
+++ +++ 
  
  
  
r of signs indicates the estimated potential value.
 limit radiation.
soesophageal echocardiography; TTE = transthoracic echocardiography.
Recommendation for (thoracic) endovascular aortic repair
((T)EVAR).
Recommendations Classa Levelb
It is recommended that the indication for
TEVAR or EVAR be decided on an individual
basis, according to anatomy, pathology,
comorbidity and anticipated durability, of
any repair, using a multidisciplinary
approach.
I C
A sufﬁcient proximal and distal landing zone of
at least 2 cm is recommended for the safe
deployment and durable ﬁxation of TEVAR.
I C
In case of aortic aneurysm, it is recommended
to select a stent-graft with a diameter
exceeding the diameter of the landing zones
by at least 10–15% of the reference aorta.
I C
During stent graft placement, invasive blood
pressure monitoring and control (either
pharmacologically or by rapid pacing) is
recommended.
I C
Preventive cerebrospinal ﬂuid (CSF) drainage
should be considered in high-risk patients.
IIa C
a Class of recommendation.
b Level of evidence.
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Aortic stiffness has independent predictive value for all-cause
and cardiovascular mortality, fatal and non-fatal coronary
events, and fatal strokes in patients with various levels of
cardiovascular risk, with a higher predictive value in subjects
with a higher baseline cardiovascular risk. Carotid-femoral
pulse wave velocity is the 'gold standard' for measuring aortic
stiffness.
5 Treatment options
5.1 Principles of medical therapy
The main aim of medical therapy in this condition is to
reduce shear stress on the diseased segment of the aorta by
reducing blood pressure and cardiac contractility. In cases
of AD, treatment with intravenous beta-blocking agents
is initiated to reduce the heart rate and lower the systolic
blood pressure to 100–120 mm Hg. Other agents may be
useful in achieving the target. In chronic conditions, blood
pressure should be controlled below 140/90 mm Hg. Use of
statins has been associated with improved survival after
AAA repair.
5.2 Endovascular therapy
5.2.1 Thoracic endovascular aortic repair (TEVAR)
5.2.1.1 Technique. Thoracic endovascular aortic repair aims at
excluding an aortic lesion from the circulation by the
implantation of a membrane-covered stent-graft across the
lesion. Contrast-enhanced CT represents the imaging modali-
ty of choice for planning TEVAR. The diameter (<40 mm) and
length (≥20 mm) of the healthy proximal and distal landing
zones are evaluated to assess the feasibility of TEVAR. In
situations involving important aortic arch side branches
TEVAR is often preceded by limited surgical revascularization
of these branches.
5.2.1.2 Complications. In TEVAR, vascular complications at
the puncture site, as well as aortic and neurological complica-
tions, and/or endoleaks have been reported. Different types of
endoleaks are illustrated in Fig. 3.
5.2.2 Abdominal endovascular aortic repair
5.2.2.1 Technique. Endovascular aortic repair is performed to
prevent infrarenal AAA rupture. The proximal aortic neck
should have a length of at least 10–15 mm and should not
exceed 32 mm in diameter. Angulation above 608 of the
proximal neck increases the risk of device migration and
endoleak. Aneurysmal disease of the iliac arteries needs
extension of the stent graft to the external iliac artery.
5.2.2.2 Complications. Immediate conversion to open surgery
is required in approximately 0.6% of patients. Endoleak is the
most common complication of EVAR. Type I and Type III
endoleaks demand correction while Type II endoleak may seal
spontaneously in about 50% of cases.5.3 Surgery
5.3.1 Ascending aorta
If the aneurysm is proximally limited to the sinotubular
junction and distally to the aortic arch, resection of the
aneurysm and supra-commissural implantation of a tubular
graft is performed. If the aneurysm extends proximally below
the sinotubular junction and one or more aortic sinuses are
dilated, the surgical repair is guided by the extent of
involvement of the aortic annulus and the aortic valve.
Reconstructive aortic root surgery, preserving the tricuspid
valve, aims for restoration of natural haemodynamics. If there
is any doubt that a durable repair can be achieved—or in the
presence of aortic sclerosis or stenosis—root replacement
should be performed with either a mechanical composite graft
or a xenograft, according to the patient's age and potential
contraindications for long-term anticoagulation.
5.3.2 Aortic arch
The continuous use of antegrade cerebral perfusion has
proven itself as safe cerebral protection. This is the case for
the majority of reconstructions, including acute and chronic
AD, requiring total arch replacement and arrest times from 40
to 60 min.
5.3.3 Descending aorta
Established methods for operation of the descending aorta
include the left heart bypass technique, the partial bypass,
and the operation in deep hypothermic circulatory arrest.
At a core temperature of 18 8C the proximal anastomosis is
performed.
5.3.4 Thoraco-abdominal aorta
When the disease affects both the descending thoracic and
abdominal aorta, the surgical approach is a left thoracotomy
extended to paramedian laparotomy.
Fig. 3 – Classification of endoleaks. Type I: Leak at graft attachment site above, below, or between graft components
(Ia: proximal attachment site; Ib: distal attachment site). Type II: Aneurysm sac filling retrogradely via single (IIa) or multiple
branch vessels (IIb). Type III: Leak through mechanical defect in graft, mechanical failure of the stent-graft by junctional
separation of the modular components (IIIa), or fractures or holes in the endograft (IIIb). Type IV: Leak through graft fabric as
a result of graft porosity. Type V: Continued expansion of aneurysm sac without demonstrable leak on imaging
(endotension, controversial).
Modified from White GH, May J, Petrasek P. Semin Interv Cardiol. 2000;5:35–46.
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The aneurysmal aorta is replaced either by a tube or bifurcated
graft, according to the extent of aneurysmal disease into the
iliac arteries. The excluded aneurysm is not resected, but is
closed over the graft.Recommendations for surgical techniques in aortic dis-
ease.
Recommendations Classa Levelb
Cerebrospinal ﬂuid drainage is recommended
in surgery of the thoraco-abdominal aorta, to
reduce the risk of paraplegia.
I B
Aortic valve repair, using the re-implantation
technique or remodelling with aortic
annuloplasty, is recommended in young
patients with aortic root dilation and
tricuspid aortic valves.
I C
For repair of acute Type A AD, an open distal
anastomotic technique avoiding aortic
clamping (hemiarch/complete arch) is
recommended.
I C
In patients with connective tissue disordersc
requiring aortic surgery, the replacement of
aortic sinuses is indicated.
I C
Selective antegrade cerebral perfusion should
be considered in aortic arch surgery, to
reduce the risk of stroke.
IIa B
The axillary artery should be considered as ﬁrst
choice for cannulation for surgery of the
aortic arch and in aortic dissection.
IIa C
Left heart bypass should be considered during
repair of the descending aorta or the thoraco-
abdominal aorta, to ensure distal organ
perfusion.
IIa C
a Class of recommendation.
b Level of evidence.
c Ehlers-Danlos IV, Marfan- or Loeys-Dietz syndromes.
Table 2 – Main clinical presentations and complications of
patients with acute aortic dissection.
Type A Type B
Chest pain 80% 70%
Back pain 40% 70%
Abrupt onset of pain 85% 85%
Migrating pain <15% 20%
Aortic regurgitation 40–75% N/A
Cardiac tamponade <20% N/A
Myocardial ischaemia or infarction 10–15% 10%
Heart failure <10% <5%
Pleural effusion 15% 20%
Syncope 15% <5%
Major neurological deﬁcit (coma/stroke) <10% <5%
Spinal cord injury <1% NR
Mesenteric ischaemia <5% NR
Acute renal ischaemia <20% 10%
Lower limb ischaemia <10% <10%
NR = not reported; NA = not applicable. Percentages are approxi-
mated.6 Acute thoracic aortic syndromes
6.1 Deﬁnition
Acute aortic syndromes are deﬁned as emergency conditions
with similar clinical characteristics involving the aorta. This
may result in IMH, PAU, or in separation of aortic wall layers,
leading to AD or even thoracic aortic rupture.
6.2 Pathology and classiﬁcation
Acute aortic syndromes occur when either a tear or an ulcer
allows blood to penetrate from the aortic lumen into the media
or when a rupture of vasa vasorum causes a bleed within the
media. Fig. 4 displays the Stanford and the DeBakey
classiﬁcations. The most common features of AAS are
displayed in Fig. 5.
6.3 Acute aortic dissection
6.3.1 Deﬁnition and classiﬁcation
Aortic dissection is deﬁned as disruption of the medial layer
provoked by intramural bleeding, resulting in separation of theaortic wall layers and subsequent formation of a TL and an FL
with or without communication. This process is followed
either by an aortic rupture in the case of adventitial disruption
or by a re-entering into the aortic lumen through a second
intimal tear. Other complications include tamponade, aortic
valve regurgitation, and proximal or distal malperfusion
syndromes.
6.3.2 Epidemiology
Up-to-date data on the epidemiology of AD are scarce. This
incidence is higher in men than in women and increases with
age. The prognosis is poorer in women, as a result of atypical
presentation and delayed diagnosis.
6.3.3 Clinical presentation and complications
6.3.3.1 Chest pain. Abrupt onset of severe chest and/or back
pain is the most typical feature. The pain may be sharp,
ripping, tearing, knife-like, and typically different from other
causes of chest pain. Cardiac complications are the most
frequent in patients with AD (Table 2).
6.3.3.2 Aortic regurgitation. In AD includes dilation of the
aortic root and annulus, tearing of valve cusps, downward
displacement of one cusp below the line of the valve closure
and loss of support of the cusp.
6.3.3.3 Myocardial ischaemia. Myocardial ischaemia or infarc-
tion may be present in 10–15% of patients with AD.
6.3.3.4 Congestive heart failure. Congestive heart failure in the
setting of AD is commonly related to aortic regurgitation.
Hypotension and shock may result from aortic rupture, acute
severe aortic regurgitation, extensive myocardial ischaemia,
cardiac tamponade, or major blood loss.
6.3.3.5 Large pleural effusions. Large pleural effusions result-
ing from aortic bleeding into the mediastinum and pleural
Fig. 4 – Classification of aortic dissection localization. Schematic drawing of aortic dissection class 1, subdivided into DeBakey
Types I, II, and III. Also depicted are Stanford classes A and B. Type III is differentiated in subtypes III A to III C (sub-type
depends on the thoracic or abdominal involvement according to Reul et al.).
Table 3 – Laboratory tests required for patients with acute
aortic dissection.
Laboratory tests To detect signs of
Red blood cell count Blood loss, bleeding, anaemia
White blood cell count Infection, inﬂammation (SIRS)
C-reactive protein Inﬂammatory response
ProCalcitonin Differential diagnosis between
SIRS and sepsis
Creatine kinase Reperfusion injury,
rhabdomyolysis
Troponin I or T Myocardial ischaemic, myocardial
infarction
D-Dimer Aortic dissection, pulmonary
embolism, thrombosis
Creatinine Renal failure (existing or
developing)
Aspartate transaminase/
alanine aminotransferase
Liver ischaemia, liver disease
Lactate Bowel ischaemia, metabolic
disorder
Glucose Diabetes mellitus
Blood gases Metabolic disorder, oxygenation
SIRS = systemic inﬂammatory response syndrome.
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up to arrival at hospital.
6.3.3.6 Pulmonary complications. Pulmonary complications of
acute AD are rare.
6.3.3.7 Syncope. Syncope is an important initial symptom of
AD!!!
6.3.3.8 Neurological symptoms. Neurological symptoms may
often be dramatic and dominate the clinical picture, masking
the underlying condition.
6.3.3.9 Mesenteric ischaemia. The perfusion disturbance can
be intermittent if caused by a dissection ﬂap prolapse, or
persistent in cases of obliteration of the organ arterial supply
by FL expansion.
6.3.3.10 Renal failure. Renal failure may be encountered at
presentation or during hospital course in up to 20% of patients
with acute Type A AD and in approximately 10% of patients
with Type B AD.
6.3.4 Laboratory testing
If D-dimers are elevated, the suspicion of AD is increased. The
level of D-dimers is immediately very high (Table 3).6.3.5 Diagnostic imaging in acute aortic dissection
The main purpose of imaging in AAD is the comprehensive
assessment of the entire aorta. Computed tomography, MRI,
Fig. 5 – Classification of acute aortic syndrome in aortic dissection. Class 1: Classic AD with true and FL with or without
communication between the two lumina. Class 2: Intramural haematoma. Class 3: Subtle or discrete AD with bulging of the
aortic wall. Class 4: Ulceration of aortic plaque following plaque rupture. Class 5: Iatrogenic or traumatic AD, illustrated by a
catheter induced separation of the intima.
Recommendations on diagnostic work-up of acute aortic
syndrome.
Recommendations Classa Levelb
History and clinical assessment
In all patients with suspected AAS, pre-test
probability assessment is recommended,
according to the patient's condition,
symptoms, and clinical features.
I B
Laboratory testing
In case of suspicion of AAS, the interpretation of
biomarkers should always be considered along
with the pretest clinical probability.
IIa C
In case of low clinical probability of AAS,
negative D-dimer levels should be considered
as ruling out the diagnosis.
IIa B
In case of intermediate clinical probability of AAS
with a positive (point-of-care) D-dimer test,
further imaging tests should be considered.
IIa B
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 2 9 7 – e 3 1 9 e307and TOE are equally reliable for conﬁrming or excluding the
diagnosis of AAD (Table 4).
6.3.5.1 Echocardiography. The diagnosis of AD by standard
transthoracic M-mode and two-dimensional echocardiogra-
phy is based on detecting intimal ﬂaps in the aorta. Limitations
of the TTE have been overcome by TOE.
6.3.5.2 Computed tomography. The key ﬁnding on contrast-
enhanced images is the intimal ﬂap separating two lumens.
‘‘Triple-rule out’’ is a relatively new term that describes an ECG-
gated 64-detector CT study to evaluate patients with acute chest
pain, in the emergency department, for three potential causes:
AD, pulmonary embolism, and coronary artery disease.
6.3.5.3 Magnetic resonance imaging. MRI is considered the
leading technique for diagnosis of AD, with a reported
sensitivity and speciﬁcity of 98%. MRI is also very useful for
detecting the presence of pericardial effusion, aortic regurgi-
tation, or carotid artery dissection.
6.3.5.4 Aortography. The angiographic diagnosis of AD is
based on 'direct' angiographic signs, such as the visualization
of the intimal ﬂap.6.3.6 Diagnostic work-up
The diagnostic work-up to conﬁrm or to rule out AD is highly
dependent on the a priori risk of this condition. The diagnostic
ﬂow chart combines the pre-test probabilities according to
clinical data, and the laboratory and imaging tests (Table 5 and
Fig. 6).
(Continued )
Recommendations Classa Levelb
In patients with high probability (risk score 2 or 3)
of AD, testing of D-dimers is not recommended.
III C
Imaging
TTE is recommended as an initial imaging
investigation.
I C
In unstablec patients with a suspicion of AAS, the
following imaging modalities are recommended
according to local availability and expertise:
 TOE I C
 CT I C
In stable patients with a suspicion of AAS, the
following imaging modalities are
recommended (or should be considered)
according to local availability and expertise:
 CT I C
 MRI I C
 TOE IIa C
In case of initially negative imaging with
persistence of suspicion of AAS, repetitive
imaging (CT or MRI) is recommended.
I C
Chest X-ray may be considered in cases of low
clinical probability of AAS.
IIb C
In case of uncomplicated Type B AD treated
medically, repeated imaging (CT or MRI)d
during the ﬁrst days is recommended.
I C
a Class of recommendation.
b Level of evidence.
c Unstable means very severe pain, tachycardia, tachypnoea,
hypotension, cyanosis, and/or shock.
d Preferably MRI in young patients, to limit radiation exposure.
AAS = abdominal aortic aneurysm; AD = aortic dissection;
CT = computed tomography; MRI = magnetic resonance imaging;
TOE = transoesophageal echocardiography; TTE = transthoracic
echocardiography.
Table 4 – Details required from imaging in acute aortic
dissection.
Aortic dissection
Visualization of intimal ﬂap
Extent of the disease according to aortic anatomic segmentation
Identiﬁcation of the false and true lumens (if present)
Localization of entry and re-entry teats (if present)
Identiﬁcation of antegrade and/or retrograde aortic dissection
Identiﬁcation grading, and mechanism of aortic valve regurgitation
Involvement of side branches
Detection of malperfusion (low ﬂow or no ﬂow)
Detection of organ ischaemia (brain, myocardium, bowel,
kidneys, etc.)
Detection of pericardial effusion and its severity
Detection and extent of pleural effusion
Detection of peri-aortic bleeding
Signs of mediastinal bleeding
Intramural haematoma
Localization and extent of aortic arch thickening
Co-existence of atheromatous disease (calcium shift)
Presence of small intimal tears
Penetrating aortic ulcer
Localization of the lesion (length and depth)
Co-existence of intramural haematoma
Involvement of the peri-aortic tissue and bleeding
Thickness of the residual wall
In all cases
Co-existence of other aortic lesions: aneurysms, plaques, signs of
inﬂammatory disease, etc.
Recommendations for treatment of aortic dissection.
Recommendations Classa Levelb
In all patients with AD, medical therapy including
pain relief and blood pressure control is
recommended.
I C
In patients with Type A AD, urgent surgery is
recommended.
I B
In patients with acute Type A AD and organ
malperfusion, a hybrid approach (i.e. ascending
aorta and/or arch replacement associated with
any percutaneous aortic or branch artery
procedure) should be considered.
IIa B
In uncomplicated Type B AD, medical therapy
should always be recommended.
I C
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Whether or not the patient undergoes any intervention,
medical therapy to control pain and the haemodynamic state
is essential.
6.3.7.1 Type A aortic dissection. Surgery is the treatment of
choice. Acute Type A AD has a mortality of 50% within the ﬁrst
48 h if not operated. Despite improvements in surgical and
anaesthetic techniques, perioperative mortality (25%) and
neurological complications (18%) remain high. Although com-
monly associated with a poor post-operative prognosis, recov-
ery has been reported when rapid brain reperfusion is achieved,
especially if the time between symptom onset and arrival at the
operating room is <5 h.
6.3.7.2 Type B aortic dissection. The course of Type B AD is
often uncomplicated so—in the absence of malperfusion or
signs of disease progression—the patient can be safely stabilized
under medical therapy alone, to control pain and blood pressure.
6.3.7.2.1 Uncomplicated Type B aortic dissection. 6.3.7.2.1.1
Medical therapy. Patients with uncomplicated Type B AD
receive medical therapy to control pain, heart rate, and blood
pressure, with close surveillance to identify signs of disease
progression and/or malperfusion.
6.3.7.2.1.2 Thoracic endovascular aortic repair. Thoracic endo-
vascular aortic repair (TEVAR) aims at stabilization of the
dissected aorta, to prevent late complications by inducingaortic remodelling processes. Obliterating the proximal inti-
mal tear by implantation of a membrane-covered stent-graft
redirects blood ﬂow to the TL, thus improving distal perfusion.
6.3.7.2.2 Complicated Type B aortic dissection: endovascular
therapy. 6.3.7.2.2.1 Thoracic endovascular aortic repair
(TEVAR). Thoracic endovascular aortic repair (TEVAR) is the
treatment of choice in complicated acute Type B AD. The term
'complicated' means persistent or recurrent pain, uncontrolled
hypertension, early aortic expansion, malperfusion, and signs
of rupture.
There is increasing evidence that TEVAR shows a signiﬁ-
cant advantage over open surgery in patients with acute
complicated Type B AD.
6.3.7.2.2.2 Surgery. Lower extremities artery disease, severe
tortuosity of the iliac arteries, a sharp angulation of the aortic
arch, and the absence of a proximal landing zone for the stent
graft are factors that indicate open surgery for the treatment of
acute complicated Type B AD.
Fig. 6 – Flowchart for decision-making based on pre-test sensiti
aneurysm; AD, aortic dissection; CT, computed tomography; MR
echocardiography; TTE, transthoracic echocardiography.
Table 5 – Clinical data useful to assess the a priori probability 
High-risk conditions High-risk pain featur
Marfan syndrome (or other connective
tissue diseases)
Chest, back, or abdominal 
described as any of the foll
Family history of aortic disease - abrupt onset 
Known aortic valve disease - severe intensity 
Known thoracic aortic aneurysm - ripping or tearing 
Previous aortic manipulation (including
cardiac surgery)
(Continued )
Recommendations Classa Levelb
In uncomplicated Type B AD, TEVAR should be
considered.
IIa B
n complicated Type B AD, TEVAR is recommended. I C
In complicated Type B AD, surgery may be
considered.
IIb C
a Class of recommendation.
b Level of evidence.
AD = aortic dissection; TEVAR = thoracic endovascular aortic repair.
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6.4.1 Deﬁnition
Aortic IMH is an entity in which a haematoma develops in the
media of the aortic wall in the absence of an FL. Intramural
haematoma is diagnosed in the presence of a circular or
crescent-shaped thickening of >5 mm of the aortic wall in the
absence of detectable blood ﬂow.vity of acute aortic syndrome. AAS, abdominal aortic
I, magnetic resonance imaging; TOE, transoesophageal
of acute aortic syndrome.
es High-risk examination features
pain
owing:
Evidence of perfusion deﬁcit:
- pulse deﬁcit
- systolic blood pressure difference
- focal neurological deﬁcit (in conjunction with pain)
Aortic systolic murmur (new and with pain)
Hypertension or shock
Table 7 – Diagnostic value of different imaging modalities
in acute aortic syndromes.
Lesion TTE TOE CT MRI
Ascending aortic dissection ++ +++ +++ +++
Aortic arch dissection + + +++ +++
Descending aortic dissection + +++ +++ +++
Size ++ +++ +++ +++
Mural thrombus + +++ +++ +++
Intramural haematoma + +++ ++ +++
Penetrating aortic ulcer ++ ++ +++ +++
Involvement of aortic branches +a (+) +++ +++
+++ = excellent; ++ = moderate; + = poor; (+) = poor and inconstant;
CT = computed tomography; MRI = magnetic resonance imaging;
TOE = transoesophageal echocardiography; TTE = transthoracic
echocardiography.
a Can be improved when combined by vascular ultrasound (carotid,
subclavian, vertebral, celiac, mesenteric and renal arteries).
Table 6 – Predictors of intramural haematoma complica-
tions.
Persistent or recurrent pain despite aggressive medical treatment
Difﬁcult blood pressure control
Ascending aortic involvement
Maximum aortic diameter ≥50 mm
Progressive maximum aortic wall thickness (>11 mm)
Enlarging aortic diameter
Recurrent pleural effusion
Penetrating ulcer or ulcer-like projection secondary to localized
dissections in the involved segment
Detection of organ ischaemia (brain, myocardium, bowel,
kidneys, etc.)
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For the detection of an acute aortic IMH, CT and MRI are the
leading techniques for diagnosis and classiﬁcation of intra-
mural haematoma.
6.4.3 Natural history, morphological changes, and
complications
The mortality rates of medically treated patients are high. The
in-hospital mortality of Type A IMH was similar to Type A AD
(Table 6).
6.4.4 Indications for surgery and thoracic endovascular aortic
repair
Therapeutic management in acute IMH should be similar to
that for AD.
6.4.4.1 Type A intramural haematoma. Emergency surgery is
indicated in complicated cases with pericardial effusion,
periaortic haematoma, or large aneurysms, and urgent surgery
is required in most of the Type A.
6.4.4.2 Type B intramural haematoma. Medical treatment is
the initial approach to this condition. Endovascular therapy or
surgery would have the same indications as for Type B AD.Recommendations on the management of intramural
haematoma.
Recommendations Classa Levelb
In all patients with IMH, medical therapy
including pain relief and blood pressure control
is recommended.
I C
In cases of Type A IMH, urgent surgery is indicated. I C
In cases of Type B IMH, initial medical therapy
under careful surveillance is recommended.
I C
In uncomplicatedc Type B IMH, repetitive
imaging (MRI or CT) is indicated.
I C
In complicatedc Type B IMH, TEVAR should be
considered.
IIa C
In complicatedc Type B IMH, surgery may be
considered.
IIb C
a Class of recommendation.
b Level of evidence.
c Uncomplicated/complicated IMH means absence or present
recurrent pain, expansion of the IMH, periaortic haematoma,
intimal disruption.
CT = computed tomography; IMH = intramural haematoma; MRI =
magnetic resonance imaging; TEVAR = thoracic endovascular aortic
repair.6.5 Penetrating aortic ulcer
6.5.1 Deﬁnition
Penetrating aortic ulcer (PAU) is deﬁned as ulceration of an
aortic atherosclerotic plaque penetrating through the internal
elastic lamina into the media. The natural history of this lesion
is characterized by progressive aortic enlargement and devel-
opment of saccular or fusiform aneurysms in the ascending
aorta (Type A PAU). The most common location of PAU is the
middle and lower descending thoracic aorta (Type B PAU).
6.5.2 Diagnostic imaging
Contrast-enhanced CT is the technique of choice for diagnosis
of PAU (Table 7).
6.5.3 Management
In the presence of AAS related to PAU, the aim of treatment is
to prevent aortic rupture and progression to acute AD. It has
been suggested that asymptomatic PAUs with diameter
>20 mm or neck >10 mm represent a higher risk for disease
progression and may be candidates for early intervention.
6.5.4 Interventional therapy
The choice of treatment is commonly based on anatomical
features, clinical presentation, and comorbidities. These aortic
lesions represent an ideal anatomical target for stenting.Recommendations on management of penetrating aortic
ulcer.
Recommendations Classa Levelb
In all patients with PAU, medical therapy
including pain relief and blood pressure
control is recommended.
I C
In the case of Type A PAU, surgery should be
considered.
IIa C
In the case of Type B PAU, initial medical
therapy under careful surveillance is
recommended.
I C
In uncomplicated Type B PAU, repetitive
imaging (MRI or CT) is indicated.
I C
In complicated Type B PAU, TEVAR should
be considered.
IIa C
Recommendations for traumatic aortic injury.
(Continued )
Recommendations Classa Levelb
In complicated Type B PAU, surgery may be
considered.
IIb C
a Class of recommendation.
b Level of evidence.
CT = computed tomography; MRI = magnetic resonance imaging;
PAU = penetrating aortic ulcer; TEVAR = thoracic endovascular
aortic repair.
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Aortic pseudoaneurysm (false aneurysm) is deﬁned as a
dilation of the aorta due to disruption of all wall layers.
Pseudoaneurysms of the thoracic aorta are commonly
secondary to blunt thoracic trauma. Iatrogenic aetiologies
include aortic surgery and catheter-based interventions. In
patients with aortic pseudoaneurysms—if feasible and inde-
pendently of size—interventional or open surgical interven-
tions are always indicated.
6.7 (Contained) rupture of aortic aneurysm
Contained rupture should be suspected in all patients
presenting with acute pain, in whom imaging detects aortic
aneurysm with preserved integrity of the aortic wall.
6.7.1 Contained rupture of thoracic aortic aneurysm
6.7.1.1 Clinical presentation. Patients with contained rupture
of a TAA usually present with acute onset of chest and/or back
pain. Concurrent abdominal pain may be present in patients
with symptomatic thoraco-abdominal aneurysms.
6.7.1.2 Diagnostic work-up. With the suspicion of (contained)
rupture of a TAA, CT is indicated. Contained ruptures of TAA
are indications for urgent treatment because of the risk of
imminent internal bleeding and death.
6.7.1.3 Treatment. Contained rupture of TAA is a condition
requiring urgent treatment. Traditionally, this condition has
been treated by open repair, but endovascular repair has
emerged as an alternative treatment option for suitable
patients case by case, depending also on local expertise.Recommendations for (contained) rupture the thoracic
aortic aneurysm.
Recommendations Classa Levelb
In patients with suspected rupture of the TAA,
emergency CT angiography for diagnosis
conﬁrmation is recommended.
I C
In patients with acute contained rupture of
TAA, urgent repair is recommended.
I C
If the anatomy is favourable and the expertise
available, endovascular repair (TEVAR)
should be preferred over open surgery.
I C
a Class of recommendation.
b Level of evidence.
CT = computed tomography; TAA = thoracic aortic aneurysm; TE-
VAR = thoracic endovascular aortic repair.6.8 Traumatic aortic injury
6.8.1 Deﬁnition, epidemiology and classiﬁcation
Most often blunt traumatic thoracic aortic injury (TAI) occurs
as a consequence of sudden deceleration resulting from head-
on or side-impact collisions, or falling from a great height. A
classiﬁcation scheme for TAI has been proposed: Type I
(intimal tear), Type II (IMH), Type III (pseudoaneurysm), and
Type IV (rupture).
6.8.2 Patient presentation and diagnosis
The clinical presentation of TAI ranges from minor non-
speciﬁc symptoms to mediastinal or interscapular pain.
Emergency CT should be performed.
6.8.3 Indications for treatment in traumatic aortic injury
Patients with free aortic rupture or large periaortic haematoma
should be treated as emergency cases. For all other conditions,
the intervention may be delayed for up to 24 h. An initial
conservative management, with serial imaging, has been
proposed for patients with minimal aortic injuries (intimal
tear/Type I lesions), as most lesions remain stable or resolve.
6.8.4 Medical therapy in traumatic aortic injury
In polytrauma patients, multidisciplinary management is vital
to establish the correct timing of the interventions and
treatment priorities.
6.8.5 Surgery in traumatic aortic injury
Open surgical repair of a TAI at the classic isthmus location
requires exposure of the aorta via a left fourth interspace
thoracotomy.
6.8.6 Endovascular therapy in traumatic aortic injury
Available data indicate that TEVAR, in suitable anatomies,
should be the preferred treatment option in TAI.
6.8.7 Long-term surveillance in traumatic aortic injury
CT is currently considered the standard imaging modality for
follow-up in patients who beneﬁt from TEVAR. It seems
rational to adopt a combination of a multiview chest X-ray and
MRI, instead of CT.Recommendations Classa Levelb
In case of suspicion of TAI, CT is recommended. I C
If CT is not available, TOE should be considered. IIa C
In cases of TAI with suitable anatomy requiring
intervention, TEVAR should be preferred to
surgery.
IIa C
a Class of recommendation.
b Level of evidence.
CT = computed tomography; TAI = traumatic aortic injury; TE-
VAR = thoracic endovascular aortic repair; TOE = transoesophageal
echocardiography.6.9 Iatrogenic aortic dissection
Iatrogenic aortic dissection (IAD) may occur in the setting of (i)
catheter-based coronary procedures, (ii) cardiac surgery, (iii) as
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 2 9 7 – e 3 1 9e312a complication of endovascular treatment of aortic coarcta-
tion, (iv) aortic endografting, (v) peripheral interventions, (vi)
intra-aortic balloon counterpulsation and, (vii) during trans-
catheter aortic valve implantation. Clinical manifestations
may range from the absence of symptoms to excruciating
chest, back, or abdominal pain, according to the site of the AD.
Hypotension, haemodynamic compromise, and shock may
ensue. Treatment is conservative in most cases, with complete
spontaneous healing observed in most instances. Dissections
extending over several centimetres into the ascending aorta or
further propagating do require emergency cardiac surgery.
7 Aortic aneurysms
Aneurysm is the second most frequent disease of the aorta after
atherosclerosis. The presence of aortic aneurysm may be
associated with other locations of aneurysms. The 10-year risk
of mortality from any other cardiovascular cause may be as high
as 15 times the risk of aorta-related death in patients with AAA.Recommendations in patients with aortic aneurysm.
Recommendations Classa Levelb
When an aortic aneurysm is identiﬁed at any
location, assessment of the entire aorta and
aortic valve is recommended at baseline and
during follow-up.
I C
In cases of aneurysm of the abdominal aorta,
duplex ultrasound for screening of peripheral
artery disease and peripheral aneurysms
should be considered.
IIa C
Patients with aortic aneurysm are at increased risk
of cardiovascular disease: general principles of
cardiovascular prevention should be considered.
IIa C
a Class of recommendation.
b Level of evidence.
Recommendations on interventions on ascending aortic
aneurysms.
Recommendations Classa Levelb
Surgery is indicated in patients who have aortic
root aneurysm, with maximal aortic diameterc
≥50 mm for patients with Marfan syndrome.
I C7.1 Thoracic aortic aneurysms
TAA encompasses a wide range of locations and aetiologies,
the most frequent being degenerative aneurysm of the
ascending aorta.
7.1.1 Diagnosis
Patients with TAA are most often asymptomatic and the
diagnosis is made following imaging performed either for this
purpose or other investigative reasons.
7.1.2 Anatomy
Marfan syndrome, aortic enlargement is generally maximal at
the sinuses of Valsalva, responsible for annulo-aortic ectasia.
In patients with BAV, three enlargement patterns are
described, according to whether the maximal aortic diameter
is at the level of the sinuses of Valsalva, the supracoronary
ascending aorta, or the sinotubular junction level.
7.1.3 Evaluation
Once aortic dilation is suspected, based on echocardiography
and/or chest X-ray, CT or MRI is required to adequately
visualize the entire aorta and identify the affected parts.7.1.3.1 Aortic growth in familial thoracic aortic aneurysms.
Familial TAAs grow faster, up to 2.1 mm/year. In patients with
Marfan syndrome, the TAA growth is on average at 0.5–1 mm/
year, whereas TAAs in patients with Loeys-Dietz syndrome
(LDS) can grow even faster than 10 mm/year, resulting in death
at a mean age of 26 years.
7.1.3.2 Descending aortic growth. TAAs of the descending aorta
grow faster (at 3 mm/year) than those in ascending aorta
(1 mm/year).
7.1.3.3 Risk of aortic dissection. There is a rapid increase in the
risk of dissection or rupture when the aortic diameter is >60 mm
for the ascending aorta and >70 mm for the descending aorta.
7.1.4 Interventions
7.1.4.1 Ascending aortic aneurysms. Surgery should be per-
formed in patients with Marfan syndrome, who have a
maximal aortic diameter ≥50 mm. A lower threshold of
45 mm can be considered in patients with additional risk
factors, including family history of dissection, size increase
>3 mm/year, severe aortic regurgitation, or desire for preg-
nancy. Earlier interventions have been proposed for aortic
diameters >42 mm in patients with LDS.
Surgery should be performed in patients with a BAV, who
have a maximal aortic diameter ≥55 mm. A lower threshold of
50 mm can be considered in patients with additional risk
factors, such as family history, systemic hypertension, coarcta-
tion of the aorta, or increase in aortic diameter >3 mm/year, and
also according to age, body size, comorbidities, and type of
surgery. Regardless of aetiology, surgery should be performed in
patients who have a maximal aortic diameter ≥55 mm.
For patients who have an indication for surgery on the
aortic valve, lower thresholds can be used for concomitant
aortic replacement (>45 mm) depending on age, body size,
aetiology of valvular disease, and intraoperative shape and
thickness of the ascending aorta.
7.1.4.2 Aortic arch aneurysms. Surgery should be considered
in patients who have an aortic arch aneurysm with a maximal
diameter ≥55 mm or who present symptoms or signs of local
compression.
7.1.4.3 Descending aortic aneurysms. The treatment of des-
cending aortic aneurysms has been re-orientated with the
development of TEVAR using stent grafts.
TEVAR should be considered in patients who have a
descending TAA with a maximal diameter ≥55 mm. When
surgery is the only option, it should be considered in patients
with a maximal diameter ≥60 mm. Surgery and TEVAR may be
combined in hybrid approaches. In cases of Marfan disease,
surgery should be preferred over TEVAR.
(Continued )
Recommendations Classa Levelb
Surgery should be considered in patients who
have aortic root aneurysm, with maximal
ascending aortic diameters:
 ≥45 mm for patients with Marfan syndrome
with risk factors.d
 ≥50 mm for patients with bicuspid valve with
risk factors.e,f
 ≥55 mm for other patients with no
elastopathy.g,h
IIa C
Lower thresholds for intervention may be
considered according to body surface area
in patients of small stature or in the case
of rapid progression, aortic valve
regurgitation, planned pregnancy, and
patient's preference.
IIb C
Interventions on aortic arch aneurysms
Surgery should be considered in patients who
have isolated aortic arch aneurysm with
maximal diameter ≥55 mm. Aortic arch
repair may be considered in patients with
aortic arch aneurysm who already have an
indication for surgery of an adjacent
aneurysm located in the ascending or
descending aorta.
IIa C
Aortic arch repair may be considered in
patients with aortic arch aneurysm who
already have an indication for surgery of an
adjacent aneurysm located in the ascending
or descending aorta.
IIb C
Interventions on descending aortic aneurysms
TEVAR should be considered, rather than
surgery, when anatomy is suitable.
IIa C
TEVAR should be considered in patients who
have descending aortic aneurysm with
maximal diameter ≥55 mm.
IIa C
When TEVAR is not technically possible,
surgery should be considered in patients who
have descending aortic aneurysm with
maximal diameter ≥60 mm.
IIa C
When intervention is indicated, in cases of
Marfan syndrome or other elastopathies,
surgery should be indicated rather than
TEVAR.
IIa C
a Class of recommendation.
b Level of evidence.
c Decision should also take into account the shape of the different
parts of the aorta. Lower thresholds can be used for combining
surgery on the ascending aorta for patients who have an indication
for surgery on the aortic valve.
d Family history of AD and/or aortic size increase >3 mm/year (on
repeated measurements using the same imaging technique, at the
same aorta level, with side-by-side comparison and confirmed by
another technique), severe aortic or mitral regurgitation, or desire
for pregnancy.
e Coarctation of the aorta, systemic hypertension, family history of
dissection, or increase in aortic diameter >3 mm/year (on repeated
measurements using the same imaging technique, measured at
the same aorta level, with side-by-side comparison and confirmed
by another technique).
f Pending comorbidities in the elderly.
g See text in Section 8.
h For patients with LDS or vascular type IV Ehlers-Danlos
syndrome (EDS), lower thresholds should be considered, possibly
even lower than in Marfan syndrome. There are no data to provide
figures and a sensible case-by-case approach is the only option.
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7.2.1 Deﬁnition
AAA—almost exclusively infrarenal—is usually deﬁned as a
diameter ≥30 mm. An alternative deﬁnition of it is a >50%
increased diameter.
7.2.2 Risk factors
Age, male gender, personal history of atherosclerotic cardio-
vascular disease, smoking and hypertension are all associated
with the presence of AAA. A family history of AAA is a
predictor of prevalent AAA.
7.2.3 Natural history
Large and life-threatening AAA is preceded by a long period of
subclinical growth in the diameter of the aneurysm, estimated
at <1–6 mm/year. The risk of rupture rises exponentially with
the aneurysm's maximal diameter and is higher in women.
7.2.4 Diagnosis
AAA is mostly silent. The most frequent mode of detection is
incidental. Acute abdominal pain and shock are usually
present in the case of ruptured AAA.
7.2.4.1 Presentation. Before its cataclysmic presentation when
ruptured, AAA is mostly silent. The most frequent mode of
detection is incidental, during abdominal imaging for any
indication. Atypical abdominal or back pain may be present but
should not be awaited in order to reach a diagnosis.
7.2.4.2 Diagnostic imaging. Ultrasonography is an excellent
tool for screening and surveillance. Considered the 'gold
standard' in the past was aortography. CT and MRI have
emerged as the current 'gold standards' in the pre-operative
and post-operative evaluation of AAAs.
7.2.4.3 Screening abdominal aortic aneurysm in high-risk
populations. The grim prognosis of ruptured AAA (mortality
>60–70%) contrasts with the excellent survival rate (>95%)
after planned AAA operation. Opportunistic screening is the
most appealing in a situation for cardiologists during
echocardiography, since abdominal aorta imaging can be
performed using the same probe.
7.2.5 Management of small abdominal aortic aneurysms
The deﬁnition of 'small' AAA varies as 30–49 mm or 30–54 mm,
the upper limit depending on the threshold set for interven-
tion. In this document, 'small' AAA encompasses situations
where endovascular or surgical intervention is not yet
considered.
7.2.5.1 Management of risk factors. Smoking was the most
important predictor of future aortic aneurysm outcomes.
Intense isometric exercise is usually discouraged.
7.2.5.2 Medical therapy. Studies suggested potential beneﬁts
of beta-blockers. Statins and ACE-inhibitors should be consid-
ered in these patients, to reduce risk of cardiovascular disease.
The use of antiplatelet therapy has been suggested to reduce
complication rates in AAA.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 2 9 7 – e 3 1 9e3147.2.5.3 Follow-up of small abdominal aortic aneurysm. Those
with an aorta diameter <25 mm can be considered to be at very
low risk of large AAA within the following 10 years, while an
initial aorta of 26–29 mm merits a new assessment after 4
years. Intervals of 3, 2, and 1 year(s) can be safely proposed for
AAAs of 30–39, 40–44 and 45–54 mm diameter, respectively.
Women with 45 mm AAA had a risk of rupture equivalent to
men with a 55 mm AAA.Recommendations on the management of asympto-
matic patients with enlarged aorta or abdominal aortic
aneurysm.
Recommendations Classa Levelb
In patients with abdominal aortic diameter of
25–29 mm, new ultrasound imaging should
be considered 4 years later.
IIa B
Surveillance is indicated and safe in patients
with AAA with a maximum diameter of
<55 mm and slow (<10 mm/year) growth.c
I A
In patients with small (30–55 mm) AAAs, the
following time interval
for imaging should be considered:c
 every 3 years for AAA of 30–39 mm diameter.
 every 2 years for AAA of 40–44 mm diameter.
 every year for AAA >45 mmd diameter.
IIa B
Smoking cessation is recommended to slow
growth of the AAA.
I B
To reduce aortic complications in patients with
small AAAs, the use of statins and ACE
inhibitors may be considered.
IIb B
AAA repair is indicated if:
 AAA diameter exceeds 55 mm.e
 Aneurysm growth exceeds 10 mm/year.
I B
If a large aneurysm is anatomically suitable for
EVAR, either open or endovascular aortic
repair is recommended in patients with
acceptable surgical risk.
I A
If a large aneurysm is anatomically unsuitable
for EVAR, open aortic repair is recommended.
I C
In patients with asymptomatic AAA who are
unﬁt for open repair, EVAR, along with best
medical treatment, may be considered.f
IIb B
a Class of recommendation.
b Level of evidence.
c With <1% risk of rupture between two AAA imaging assess-
ments.
d This interval maybe shortened in women or in the case of rapid
growth between previous assessments.
e Individual decision for operative aneurysm correction should
also be influenced by the patient's gender. At a given size, AAAs in
women are up to four times as likely to rupture under surveillance,
thus aortic repair can be discussed at a lower threshold of probably
50 mm. The patient's life expectancy should also be considered
prior to decision for intervention.
f Since only aneurysm-related and not all-cause mortality is
improved, informed patient choice is to be taken into account.
AAA = abdominal aortic aneurysm; ACE = angiotensin-converting
enzyme; EVAR = endovascular aortic repair.
Recommendations for abdominal aortic aneurysm
screening.
Recommendations Classa Levelb
Population screening for AAA with ultrasound:
 is recommended in all men >65 years of age. I A
 may be considered in women >65 years of
age with history of current/past smoking.
Ib C
 is not recommended in female nonsmokers
without familial history.
III C
Targeted screening for AAA with ultrasound
should be considered in ﬁrst-degree siblings
of a patient with AAA.
IIa B
Opportunistic screening for AAA during TTE:
 should be considered in all men > 65 years of
age.
IIa B
 may be considered in women >65 years with
a history of current/past smoking.
IIb C
a Class of recommendation.
b Level of evidence.
AAA = abdominal aortic aneurysm; TTE = transthoracic echocar-
diography.7.2.6 Abdominal aortic aneurysm repair
7.2.6.1 Pre-operative cardiovascular evaluation. Coronary ar-
tery disease is the leading cause of early mortality after surgery
for AAA. Endovascular AAA repair procedures carry a lower
risk (1–5%) than open surgery.
7.2.6.2 Aortic repair in asymptomatic abdominal aortic aneur-
ysm. The management of AAA depends on aneurysm diame-
ter. The aneurysm—until it reaches 55 mm or becomes
symptomatic or fast growing (>10 mm/year)—is regarded as
a safe strategy for intervention in patients with small AAAs.
Diameter in women, intervention at a smaller diameter
(>50 mm) may be justiﬁed.
7.2.6.3 Open aortic aneurysm repair. Open AAA repair has
been regarded as the default surgical intervention for AAA, but
it carries a certain risk of mortality and morbidity. Outcomes of
open ruptured AAA repair are much worse than those for
elective AAA repair.
7.2.6.4 Endovascular aortic aneurysm repair. The greatest
advantage of EVAR is in its less invasive nature with lower
mortality rates, at 1.4%, in recent studies. On the other hand,
the long-term efﬁcacy of EVAR remains a matter of concern.
7.2.6.5 Comparative considerations of abdominal aortic aneur-
ysm management. Endovascular aortic repair is a valid
alternative to surgical repair of AAA; however, in patients
with more complex aortic anatomy open repair remains thestandard. For all other AAA aneurysms that are not suitable for
EVAR, open repair remains the reference standard.
7.2.7 (Contained) rupture of abdominal aortic aneurysm
7.2.7.1 Clinical presentation. The classic presentation of rup-
tured AAA includes abdominal pain or back pain, hypotension,
and abdominal pulsatile mass.7.2.7.2 Diagnostic work-up. In the presence of free, ruptured
AAA, massive periaortic bleeding involving the perirenal or
pararenal spaces, as well as free ﬂuid in the peritoneal space,
allows for a straightforward diagnosis even with ultrasound.
Computed tomography is the imaging method of choice in the
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rupture of an AAA.
7.2.7.3 Treatment. The recently published results showed no
signiﬁcant difference between EVAR and open repair. Women
are exposed to higher periprocedural mortality in elective open
and endovascular aneurysm repair.
7.2.8 Long-term prognosis and follow-up of aortic aneurysm
repair
Most patients require a convalescence period of up to 3
months after open AAA repair, after which quality-of-life
scores are similar for endovascular and open AAA repair, and
even slightly better for open repair at 1 year.Recommendations on genetic testing in aortic diseases.
Recommendations Classa Levelb
It is recommended to investigate ﬁrst-degree
relatives (siblings and parents) of a subject
with TAAD to identify a familial form in
which relatives all have a 50% chance of
carrying the family mutation/disease.
I C
Once a familial form of TAAD is highly
suspected, it is recommended to refer the
patient to a geneticist for family investigation
and molecular testing.
I C
Variability of age of onset warrants screening
every 5 years of 'healthy' at-risk relatives
until diagnosis (clinical or molecular) is
established or ruled out.
I C
In familial non-syndromic TAAD, screening for
aneurysm should be considered, not only in
the thoracic aorta, but also throughout the
arterial tree (including cerebral arteries).
a Class of recommendation.
b Level of evidence.
TAAD = thoracic aortic aneurysms and dissection.
Recommendations on management of patients with
symptomatic abdominal aortic aneurysm.
Recommendations Classa Levelb
In patients with suspected rupture of AAA,
immediate abdominal ultrasound or CT is
recommended.
I C
In case of ruptured AAA, emergency repair is
indicated.
I C
In case of symptomatic but non-ruptured AAA,
urgent repair is indicated.
I C
In case of symptomatic AAA anatomically
suitable for EVAR, either open or
endovascular aortic repair is recommended.c
I A
a Class of recommendation.
b Level of evidence.
c Depending on the expertise of the interventional team and
patient's level of risk.
AAA = abdominal aortic aneurysm; CT = computed tomography;
EVAR = endovascular aortic repair.8 Genetic diseases affecting the aorta
Genetic diseases affecting the aorta are broadly split into two
categories: syndromic and non-syndromic, both essentially
displaying autosomal dominant transmission.
8.1 Chromosomal and inherited syndromic thoracic aortic
aneurysms and dissection
8.1.1 Turner syndrome (TS)
Turner syndrome (TS) is essentially caused by partial or
complete monosomy of the X chromosome (karyotype 45X0).
8.1.2 Marfan syndrome
It is the most frequent heritable connective tissue disorder.
8.1.3 Ehlers-Danlos syndrome Type IV
Ehlers-Danlos syndrome Type IV (EDSIV) is a rare, autosomal,
dominant connective tissue disorder caused by mutations in
the COL3A1 gene coding for Type III procollagen.
8.1.4 Loeys-Dietz syndrome
Loeys-Dietz syndrome (LDS) is an autosomal dominant aortic
aneurysm syndrome combining the triad of arterial tortuosityand aneurysms throughout the arterial tree, hypertelorism,
and biﬁd uvula.
8.1.5 Arterial tortuosity syndrome
Arterial tortuosity syndrome characterized by arterial tortu-
osity, elongation, stenosis, and aneurysm of the large- and
middle-sized arteries, arterial tortuosity syndrome (ATS) is a
very rare autosomal recessive disease.
8.1.6 Aneurysms-osteoarthritis syndrome
Aneurysms-osteoarthritis syndrome (AOS) is a new syndromic
TAAD that accounts for approximately 2% of familial TAAD.
8.1.7 Non-syndromic familial thoracic aortic aneurysms and
dissection
In these patients, familial aggregation with an affected ﬁrst-
degree relative is found in up to 19% of cases.8.1.8 Genetics and heritability of abdominal aortic aneurysm
The proportion of patients with AAA who have ﬁrst-degree
relatives with the disease is usually low although it does vary
between 1% and 29%.
8.2 Aortic diseases associated with bicuspid aortic valve
8.2.1 Epidemiology
8.2.1.1 Bicuspid aortic valve (BAV). BAV is the most common
congenital cardiac defect, with a prevalence at birth of 1–2%.
8.2.1.2 Ascending aorta growth in bicuspid valves. Aortic
dilation, deﬁned as an aorta diameter of >40 mm irrespective
of body surface area, or of >27.5 mm/m2, is frequently
associated with BAV. BAV is a risk factor for dissection and
rupture. Average annual changes in the ascending aorta in
patients with BAV may vary from 0.2 to 1.2 mm/year.
8.2.1.3 Aortic dissection. The prevalence of BAV ranges from
2 to 9% in Type A AD and 3% in Type B AD.
(Continued )
Recommendations Classa Levelb
Serial measurement of the aortic root and
ascending aorta is indicated in every
patient with BAV, with an interval
depending on aortic size, increase in size
and family history.
I C
In the case of a diameter of the aortic root or
the ascending aorta > 45 mm or an
increase >3 mm/year measured by
echocardiography, annual measurement
of aortic diameter is indicated.
I C
In the case of aortic diameter >50 mm or an
increase >3 mm/year measured by
echocardiography, conﬁrmation of the
measurement is indicated, using another
imaging modality (CT or MRI).
I C
In cases of BAV, surgery of the ascending
aorta is indicated in case of:
 aortic root or ascending aortic diameter
>55 mm.
 aortic root or ascending aortic diameter
>50 mm in the presence of other risk
factors.c
 aortic root or ascending aortic diameter
>45 mm when surgical aortic valve
replacement is scheduled.
I C
Beta-blockers may be considered in patients
with BAV and dilated aortic root >40 mm.
IIb C
Because of familial occurrence, screening of
ﬁrst-degree relatives should be
considered.
IIa C
In patients with any elastopathy or BAV
with dilated aortic root (> 40 mm),
isometric exercise with a high static load
(e.g. weightlifting) is not indicated and
should be discouraged.
III C
a Class of recommendation.
b Level of evidence.
c Coarctation of the aorta, systemic hypertension, family history of
dissection, or increase in aortic diameter >3 mm/year (on repeated
measurements using the same imaging technique, measured at
the same aortic level, with side-by-side comparison and confirmed
by another technique).
BAV = bicuspid aortic valve; CT = computed tomography; MRI = -
magnetic resonance imaging; TTE = transthoracic echocardiogra-
phy.
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prevalence of aortic coarctation in BAV are scarce; one report
states it as 7%.
8.2.2 Natural history
Mean progression is reported to be 1–2 mm/year. Rapid
progression of >5 mm/year and larger diameters are associat-
ed with increased risk of AD or rupture A higher gradient
across a stenotic BAV. The re-operation for an aortic root with
a diameter of 40–50 mm during the valve replacement is rarely
necessary after a follow-up of >10 years.
8.2.3 Pathophysiology
Notch 1 gene mutations are associated with BAV.
8.2.4 Diagnosis
8.2.4.1 Clinical presentation. BAV, with stenosis or regurgita-
tion, can give rise to complaints and clinical signs. A small
subset of patients with BAV (<15%), almost exclusively young
men, presents predominantly with aortic root dilation without
substantial valvular stenosis or regurgitation.
8.2.4.2 Imaging. There are no speciﬁc comments regarding
imaging of the aorta in this setting.
8.2.4.3 Screening in relatives. Screening of ﬁrst-degree rela-
tives may be considered because of BAV's strong familial
association.
8.2.4.4 Follow-up. The patient with BAV, the aortic root and
ascending aorta should be visualized with TTE alone or
associated with another imaging modality, preferably MRI.
In cases of an increase in diameter >3 mm/year or a
diameter of 45 mm, annual follow-up of the ascending aorta
is advised.
8.2.5 Treatment
It is common clinical practice to advise beta-blocker therapy.
The indication for surgical treatment of aortic dilation in BAV is
similar to that for other causes of dilation. When surgery is
indicated for BAV, stenosis or regurgitation, aortic root
replacement should be considered if the root is larger than
45 mm in diameter.
8.2.6 Prognosis
The risk of dissection and rupture increases with the diameter
of the aorta, with a sharp increase at a diameter of 60 mm.Recommendations for the management of aortic root
dilation in patients with bicuspid aortic valve.
Recommendations Classa Levelb
Patients with known BAV should undergo
an initial TTE to assess the diameters
of the aortic root and ascending
aorta.
I C
Cardiac MRI or CT is indicated in patients
with BAV when the morphology of the
aortic root and the ascending aorta cannot
be accurately assessed by TTE.
I C8.3 Coarctation of the aorta
8.3.1 Background
Coarctation of the aorta is typically located at the area of ductus
arteriosus insertion.
8.3.2 Diagnostic work-up
Clinical features include upper body systolic hypertension,
lower body hypotension, and a blood pressure gradient
between the upper and lower extremities. Echocardiography
provides information regarding site, structure, and extent of
coarctation of the aorta, LVH and aortic and supra-aortic vessel
diameters. MRI and CT are the preferred non-invasive
techniques to evaluate the entire aorta in adults. Cardiac
catheterization indicates a haemodynamically signiﬁcant
coarctation of the aorta and angiography is still the 'gold
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before and after operative or interventional treatment.
8.3.3 Surgical or catheter interventional treatment
In native coarctation of the aorta with appropriate anatomy,
stenting has become the treatment of ﬁrst choice in adults in
many centres.Recommendations on management of aortic plaque.
Recommendations Classa Levelb
In the presence of aortic atherosclerosis,
general preventive measures to control risk
factors are indicated.
I C
In the case of aortic plaque detected during the
diagnostic work-up after stroke or peripheral
embolism, anticoagulation or antiplatelet
therapy should be considered. The choice
between the two strategies depends on
comorbidities and other indications for these
treatments.
IIa C
Prophylactic surgery to remove high-risk aortic
plaque is not recommended.
III C
a Class of recommendation.
b Level of evidence.
Recommendations on interventions in coarctation of the
aorta.
Recommendations Classa Levelb
In all patients with a non-invasive pressure
difference >20 mm Hg between upper and
lower limbs, regardless of symptoms but with
upper limb hypertension (>140/90 mm Hg in
adults), abnormal blood pressure response
during exercise, or signiﬁcant left ventricular
hypertrophy, an intervention is indicated.
I C
Independent of the pressure gradient,
hypertensive patients with >50% aortic
narrowing relative to the aortic diameter at
the diaphragm level (on MRI, CT, or invasive
angiography) should be considered for
intervention.
IIa C
Independent of the pressure gradient and
presence of hypertension, patients with
>50% aortic narrowing relative to the aortic
diameter at the diaphragm level (on MRI, CT,
or invasive angiography) may be considered
for intervention.
IIb C
a Class of recommendation.
b Level of evidence.
CT = computed tomography; MRI = magnetic resonance imaging.9 Atherosclerotic lesions of the aorta
9.1 Thromboembolic aortic disease
Aortic plaques consist of the accumulation of lipids in the
intima-media layer of the aorta. Secondary inﬂammation,
ﬁbrous tissue deposition, and surface erosions with subse-
quent appearance of thrombus may cause either thrombotic or
atherosclerotic embolism.
9.1.1 Epidemiology
Aortic plaques are associated with cerebrovascular and
peripheral embolic events. Aortic plaques ≥4 mm were
independent predictors of recurrent brain infarction and any
vascular events.
9.1.2 Diagnosis
TTE offers good imaging of the aortic root and proximal
ascending aorta. Multislice computed tomography can offer
excellent imaging of aortic atheromas. Magnetic resonance
imaging can give details on the composition of plaques.
9.1.3 Therapy
9.1.3.1 Antithrombotics (antiplatelets vs. vitamin K antago-
nists). Because of the thromboembolic risk, antiplatelet
therapy or anticoagulation is considered.9.1.3.2 Lipid-lowering agents. No randomized trials are avail-
able to support the use of statins.
9.1.3.3 Surgical and interventional approach. There are limited
data and no clear evidence to recommend prophylactic
endarterectomy or aortic arch stenting for prevention of stroke.9.2 Mobile aortic thrombosis
Mobile thrombi in the aorta of young patients without diffuse
atherosclerosis have been reported since the regular use of
TOE in patients with cerebral or peripheral emboli.
9.3 Atherosclerotic aortic occlusion
Abdominal aortic occlusion is rare and results in a major threat
of leg amputation or death. The diagnosis is mostly made with
the use of Doppler ultrasonography. CT or MRI yield more
detailed information that can guide the planning of treatment.
Treatment may be bypass grafting or aorto-iliac endarterecto-
my. Endovascular therapy has also been proposed.
9.4 Calciﬁed aorta
Calciﬁcation occurs in the media, and the amount of
calciﬁcation is directly associated with the extent of athero-
sclerosis (porcelain aorta).
9.5 Coral reef aorta
'Coral reef' aorta is a very rare calcifying stenotic disease of the
juxta renal and suprarenal aorta.
10 Aortitis
10.1 Deﬁnition, types, and diagnosis
Aortitis is the general term used to deﬁne inﬂammation of the
aortic wall. The most common causes of aortitis are non-
infectious inﬂammatory vasculitis.
Recommendations for follow-up and management of
chronic aortic diseases.
Recommendations Classa Levelb
Chronic aortic dissection
Contrast CT or MRI is recommended, to conﬁrm
the diagnosis of chronic AD.
I C
Initial close imaging surveillance of patients with
chronic AD is indicated, to detect signs of
complications as soon as possible.
I C
In asymptomatic patients with chronic
dissection of the ascending aorta, elective
surgery should be considered.c
IIa C
In patients with chronic AD, tight blood pressure
control <130/80 is indicated.
I C
Surgical repair or TEVAR is recommended for
complicated Type B AD (aortic diameter
>60 mm, >10 mm/year growth, malperfusion or
recurrent pain).
I C
Follow-up after endovascular treatment for aortic diseases
After TEVAR or EVAR, surveillance is
recommended after 1 month, 6 months, 12
months, and then yearly. Shorter intervals can
be proposed in the event of abnormal ﬁndings
requiring closer surveillance.
I C
CT is recommended as the ﬁrst-choice imaging
technique for follow-up after TEVAR or EVAR.
I C
If neither endoleak nor AAA sac enlargement is
documented during ﬁrst year after EVAR, then
colour DUS, with or without contrast agents,
should be considered for annual postoperative
surveillance, with non-contrast CT imaging
every 5 years.
IIa C
For patients with TAA <45 mm, annual imaging
is recommended; while in patients with TAA
45 mm and <55 mm, imaging every 6 months is
recommended, unless the stability of the
lesions is conﬁrmed by serial imaging.
I C
For follow-up after (T)EVAR in young patients, MRI
should be preferred to CT for magnetic
resonance compatible stent grafts, to reduce
radiation exposure.
IIa C
Long-term surveillance of open abdominal aortic
repair may be considered at loose (5-year)
intervals using colour DUS or CT imaging.
IIb C
a Class of recommendation.
b Level of evidence.
c Pending comorbidities and perioperative risk.
AAA = abdominal aortic aneurysm; AD = aortic dissection;
CT = computed tomography; DUS = duplex ultrasonography;
EVAR = endovascular aortic repair; MRI = magnetic resonance ima-
ging; TAA = thoracic aortic aneurysm; TEVAR = thoracic endovas-
cular aortic repair.
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Giant cell arteritis tends to affect the older population, more
often by far in women than in men. Echocardiography, CT, or
MRI are recommended. PET scanning has suggested that
subclinical aortic inﬂammation is often present in patients
with GCA.
10.1.2 Takayasu arteritis
Takayasu arteritis is a rare, large-vessel vasculitis of unknown
aetiology, typically affecting young women. Echocardiogra-
phy, MRI, and CT are useful in demonstrating homogeneous
circumferential thickening of the aortic wall with a uniform
smooth internal surface. Inﬂammation biomarkers are elevat-
ed. Pentraxin-3 may have a better accuracy in differentiating
the active- from the inactive phase of Takayasu arteritis.
10.2 Treatment
In non-infectious aortitis, corticosteroids are the standard initial
therapy. Nearly half of the patients require additional immuno-
suppression. Second-line agents include methotrexate, azathi-
oprine, and anti-tumour necrosis factor-alpha agents.
11 Aortic tumours
11.1 Primary malignant tumours of the aorta
Primary malignant tumours of the aorta are an extremely rare.
The prognosis for aortic sarcomas is poor, with metastatic
disease leading to death in a short time in most patients.
12 Long-term follow-up of aortic diseases
Patients with aortic disease usually require life-long surveil-
lance.
12.1 Chronic aortic dissection
Now accepted practice is to further divide the time course of
AD into acute (<14 days), sub-acute (15–90 days), and chronic
(>90 days) phases. Patients with chronic AD also include those
previously operated for Type A AD, with persisting dissection
of the descending aorta. Patients with newly diagnosed
chronic AD are often asymptomatic. Patients may also present
symptoms related to the enlarging dissected aorta or chronic
malperfusion or acute chest pain indicating rupture. In
patients with chronic, uncomplicated Type B AD, a primary
approach with medical therapy and repetitive clinical and
imaging follow-up is recommended. Patients with chronic
Type B AD that is complicated by progressive thoracic aortic
enlargement (>10 mm/year), FL aneurysms (with total aortic
diameter >60 mm), malperfusion syndrome, or recurrent pain,
require TEVAR or surgical treatment.
12.2 Follow-up after thoracic aortic intervention
Regular clinical follow-up is necessary, more frequently within
the ﬁrst year after diagnosis or intervention and then on ayearly basis. After aortic surgery, less-strict imaging intervals
may be sufﬁcient.
12.3 Follow-up of patients after intervention for
abdominal aortic aneurysm
Computed tomography is the ﬁrst choice for follow-up
imaging after EVAR; Duplex ultrasound is speciﬁc for the
detection of endoleaks after EVAR. Magnetic resonance
imaging has high diagnostic accuracy for detection of
endoleaks after EVAR. All patients should be provided with
the best current medical treatment protocol.
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This Task Force emphasizes the need for scientiﬁc networking
and multicentre trials on several aspects of the management
of aortic diseases. The Task Force highlights, brieﬂy, major
gaps in evidence that need further research as a priority.
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